Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2818-2824

  Raut, Chandrajit P ^a   Nucci, Marisa R ^a   Wang, Qian ^a   Manola, Judith ^a   Bertagnolli, Monica M ^a   Demetri, George D ^a   Morgan, Jeffrey A ^a   Muto, Michael G ^a   Fletcher, Christopher D M ^a   George, Suzanne ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AJCC; FIGO; Leiomyosarcoma; Predictive value; Staging system; Uterine leiomyosarcoma; Uterine sarcoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; UTERINE NEOPLASMS;

EID: 70350008454     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.030     Document Type: Article

References (20)

1. Echt G., Jepson J., Steel J., et al. Treatment of uterine sarcomas. Cancer 6 (1990) 35-39
2. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 9 (2003) 460-469
3. Olah K.S., Dunn J.A., and Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Brit J Obstet Gynaecol 9 (1992) 590-594
4. Blom R., Guerrieri C., Stal O., et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 8 (1998) 54-61
5. Ferrer F., Sabater S., Farrus B., et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 4 (1999) 47-52
6. Gadducci A., Landoni F., Sartori E., et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62 (1990) 25-32
7. Larson B., Silfversward C., Nilsson B., et al. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981. Acta Oncol 29 (1990) 185-191
8. Livi L., Paiar F., Shah N., et al. Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys 57 (2003) 1366-1373
9. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group Study. Cancer 71 (1993) 1702-1709
10. Mayerhofer K., Obermair A., Windbichler G., et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74 (1999) 196-201
11. Nordal R.R., Kristensen G.B., Kaern J., et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 34 (1995) 797-802
12. Nordal R.R., Kristensen G.B., Stenwig A.E., et al. Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol 70 (1998) 45-48
13. Nordal R.R., and Thoresen S.O. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 33 (1997) 907-911
14. Pautier P., Genestie C., Rey A., et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 (2000) 1425-1431
15. Sagae S., Yamashita K., Ishioka S., et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 67 (2004) 33-39
16. Wu T.I., Chang T.C., Hsueh S., et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 100 (2006) 166-172
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Hermanek P. Why TNM system for staging gynaecologic tumours?. CME J Gynecol Oncol 6 (2001) 267-269
19. Kapp D.S., Shin J.Y., and Chan J.K. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112 (2008) 820-830
20. Zivanovic O., Leitao M.M., Iasonos A., et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. J Clin Oncol 27 (2009) 2066-2072